If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

  • There is currently no data for BMK

SalmoBreed breakthrough

30 Sep 2015 07:00

RNS Number : 6325A
Benchmark Holdings PLC
30 September 2015
 

30 September 2015

Benchmark Holdings plc

("Benchmark" or the "Company")

 

SalmoBreed achieves major breakthrough in salmon breeding selection for sea lice and Pancreas Disease resistance

 

Benchmark Holdings is pleased to announce that its subsidiary SalmoBreed AS ("SalmoBreed") has achieved a major breakthrough in genetic breeding programs for Pancreas Disease (PD) and sea lice resistance through a new genetic method in aquaculture called Genomic Selection. This method is already recognized in genetic science for other species, and can provide a more accurate and safer selection than by using traditional methods, but has never been used in aquaculture before. Benchmark believes that the use of this method can provide a significant advancement in developing resistance to both PD and sea lice in salmon, and thus provide significant savings for the industry.

SalmoBreed's geneticists have been very satisfied with the accuracy of the results achieved from this new method thus far. It has long been proven that Genomic Selection provides increased genetic gain and reduced rate of inbreeding in species such as cattle, pigs and poultry. For the first time, SalmoBreed can implement this technology in salmon breeding as well, initially for PD and sea lice resistance. Through Genomic Selection the selection of parent broodfish is based on both phenotypic data (the physical expressions of a desired trait) and information from a large number of DNA-markers. In the case of PD and sea lice resistance, SalmoBreed utilizes approximately 50,000 DNA-markers (called SNPs).

PD Resistance

When breeding for PD resistance, SalmoBreed has previously used family information from challenge tests and Quantitative Trait Loci (QTL) testing, which relies on correlations or trends between genes from a limited segment on the genome, resulting in a potentially significant genetic variation of the desired trait. By using Genomic Selection instead of QTL, the Company looks at the whole genome of the fish and can thus access a more complete picture of how the genetic architecture looks for the desired trait, resulting in a more accurate selection of broodstock.

Sea Lice Resistance

When addressing sea lice resistance, SalmoBreed has previously developed genetic ranking based on family information from challenge tests. This meant distinction was only possible between families, without knowledge of the characteristics of the individual broodstock within each family. With Genomic Selection, it is possible to select those individuals showing the highest resistance to sea lice within each separate family, and hence get a stronger assurance that the eggs supplied have the desired genetic value of the trait of interest.

Genetic Selection allows for the selection of the best individual broodstock from all families, with the resulting increase in genetic progress and reduced rate of inbreeding creating a more sustainable breeding program. This means it will be possible to reduce the number of artificial sea lice treatments in the sea and result in future cost savings. The presence of fewer lice treatments is important for fish welfare, environment and working environment.

This is not only a breakthrough for Benchmark, but also for the entire salmon industry, which will have the opportunity to make use of the results from salmon fry already produced this autumn. Whilst definitive results in terms of efficacy are yet to be established, this advance in technology and method signals a step change in the salmon breeding industry, both in terms of efficiency and animal welfare.

The R&D leading to the application of Genomic Selection in salmon was conducted in cooperation with Nofima and other partners through an innovation project supported by the NFR (The research council of Norway). Further development of the Genomic Selection method for implementation in the Company's breeding program is being performed in cooperation with Nofima and Akvaforsk Genetic Center (AFGC), a sister company of SalmoBreed within Benchmark's Breeding and Genetics division.

"We are very proud of our success in adopting Genomic Selection for two important traits in our breeding program" said SalmoBreed's CEO, Dr. Jan-Emil Johannessen.

Malcolm Pye, CEO of Benchmark, commented, "It is fantastic to see SalmoBreed embracing the collaborative approach to innovation which typifies Benchmark's culture. The use of Genomic Selection is a major breakthrough for the salmon genetics industry, allowing us to be far more specific in our broodstock identification and resulting in a more sustainable process for both the animals themselves and their wider environment."

ENDS

For further information, please contact: 

SalmoBreed AS

Tel: 900 71585

Jan-Emil Johannessen, CEO

Dr. Borghild Hillestad

 

Cenkos Securities PLC

Tel: 020 7397 8900

Ivonne Cantu (NOMAD)

Russell Kerr (Sales)

 

Tavistock Communications

Tel: 020 7920 3150

Matt Ridsdale/ Niall Walsh

 

About SalmoBreed AS

SalmoBreed is a world leader in breeding and genetics of Atlantic salmon. It is headquartered in Bergen and owned by the British AIM-traded company Benchmark Holdings plc.

More information on www.salmobreed.no 

 

Notes to Editors:

 

Founded in 2000, Benchmark represents a new model in sustainable business development based on applied biotechnology. Over the last decade it has built a successful group of companies on the economics of a sustainable food chain. The company is growing in response to a rapidly increasing demand for sustainable food, and in particular for seafood, from both mature and emerging markets.

The Group has four divisions: Animal Health which researches, manufactures and markets medicines and vaccines particularly for aquaculture; Sustainability Science which researches and informs sustainable development in the food industry, Technical Publishing which effects technology transfer through online publishing and education, and Animal Breeding and Genetics which is the second largest supplier of salmon eggs and genetic expertise in the world. Benchmark operates internationally with offices in the UK, Ireland, Norway, USA, Brazil, China, Russia, Iceland, Thailand, Belgium, Chile, Spain, Germany, Portugal and Australia and, as at 29 September 2015, employs 396 people. 

 

Benchmark is an ethical company with an explicit policy based on the "3E's" definition of a sustainable business - ethics, environment and economics - which guides its strategy and operations.

 

For further information on Benchmark please visit www.bmkholdings.com

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUKARRVRAKUUR
Date   Source Headline
2nd Jul 20187:00 amRNSAppointment of Executive Director
29th Jun 20187:00 amRNSTotal Voting Rights
27th Jun 20184:36 pmRNSHolding(s) in Company
25th Jun 20184:01 pmRNSHolding(s) in Company
22nd Jun 20184:31 pmRNSHolding(s) in Company
22nd Jun 20187:00 amRNSDIRECTOR DEALINGS
19th Jun 20184:06 pmRNSUpdate on Joint Venture and Placing
19th Jun 20187:00 amRNSInterim Results
8th Jun 20187:00 amRNSJoint Venture, Placing and Trading Update
31st May 20187:00 amRNSTotal Voting Rights
8th May 20187:00 amRNSAppointment of Chairman
30th Apr 201812:23 pmRNSTotal Voting Rights
9th Apr 201811:14 amRNSHolding(s) in Company
5th Apr 20183:58 pmRNSHolding(s) in Company
3rd Apr 20187:00 amRNSTotal Voting Rights
27th Mar 20187:00 amRNSBenchmark hosts Capital Markets Day today
21st Mar 20187:00 amRNSBlock listing six monthly return
8th Mar 20181:37 pmRNSResult of AGM
7th Feb 20189:05 amRNSDirector Dealings
31st Jan 20187:00 amRNSBoard Succession
31st Jan 20187:00 amRNSTotal Voting Rights
25th Jan 201811:54 amRNSDirector Share Options
24th Jan 20183:17 pmRNSHolding(s) in Company
24th Jan 20181:01 pmRNSDirector Dealings
24th Jan 20187:00 amRNSPosting of Annual Report & Notice of AGM
23rd Jan 20187:08 amRNSFinal Results
19th Jan 20184:40 pmRNSSecond Price Monitoring Extn
19th Jan 20184:35 pmRNSPrice Monitoring Extension
5th Jan 20184:19 pmRNSHolding(s) in Company
4th Jan 20184:41 pmRNSSecond Price Monitoring Extn
4th Jan 20184:35 pmRNSPrice Monitoring Extension
12th Dec 20177:00 amRNSCommercial scale field trial of sea lice treatment
7th Dec 20177:00 amRNSBenchmark participates in gene editing research
5th Dec 20177:00 amRNSTrading Update and Notice of Results
8th Nov 20177:00 amRNSDevelopment of disease-resistant shrimp
6th Nov 201712:20 pmRNSReplacement: Directorate Change
6th Nov 20177:00 amRNSDirectorate Change
30th Oct 20177:00 amRNSLand-based Broodstock Facility Reaches Milestone
17th Oct 20177:00 amRNSNew Vaccine Facility Delivers First Production
10th Oct 20172:41 pmRNSHolding(s) in Company
21st Sep 20177:00 amRNSBlock Listing Six Monthly Return
8th Sep 20177:00 amRNSTrading Update
22nd Aug 20177:00 amRNSRenewal of Sales and Marketing Agreement
16th Aug 20177:00 amRNSLaunch of breakthrough purification system
28th Jul 20172:57 pmRNSDirector leave of absence
27th Jun 20177:02 amRNSHalf-year Report
19th Jun 20173:00 pmRNSNotice of Results
25th May 20177:00 amRNSTrading Update and Notice of Results
2nd May 20177:00 amRNSTotal Voting Rights
26th Apr 201710:54 amRNSDirector Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.